OCS
Oculis Holding AG
NASDAQ · Healthcare · Biotechnology · CH
$12.17
+0.00%Margins
Gross margin
35.2%
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-36.3%
Return on equity
-31.8%
Return on assets
-39.3%
Return on invested capital
0.00x
Asset turnover
-$81.6M
Cash from operations
$0.00
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026